Immune Checkpoint Inhibition

Webinar Two

Release Date:  July 1, 2020, Expiration Date:  June 30, 2022

Learning Objectives:

  1. Participants will be able to describe immune checkpoints. 
  2. Participants will be able to understand how checkpoints are leverages by cancer. 
  3. Participants will be able to describe therapies that target immune checkpoints.  

Target Audience:

This lecture is attended for primary care physicians, specialty physicians, physician assistants and nurses.


The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 


The University of Florida College of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Planning Committee Disclosure:

Conflict of interest information for the CME Advisory Committee members can be found on the following website:

Faculty Disclosure:

Dr. Rahman has disclosed that she has no relevant financial disclosures.  No one else in a position to control content has any financial relationships to disclose.

Bibliographic Sources:

DOI: 10.1200/jco.2012.30.15_suppl.7509 Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012) 7509-7509.   

Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015;125(9):3377–3383. 

Back to CME Series Main Page